Arcus Biosciences (RCUS) Misses Q3 EPS by 5c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.11), $0.05 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.46 million versus the consensus estimate of $9.47 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance